Collaboration and licensing agreement for GalXC RNAi technology platform to progress new drug targetsCollaboration and Licensing Agreement • July 7th, 2024 • New York
Contract Type FiledJuly 7th, 2024 JurisdictionThis milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the Company expects to receive in the fourth quarter of 2021.